Part I: Development and optimization of solid-lipid nanoparticles using Box-Behnken statistical design for ocular delivery of gatifloxacin

Journal of Biomedical Materials Research - Part A

Volumn 101 A, Issue 6, 2013, Pages 1813-1827

  Kalam, Mohd Abul ^a,b   Sultana, Yasmin ^b   Ali, Asgar ^b   Aqil, Mohd ^b   Mishra, Anil K ^c   Aljuffali, Ibrahim A ^a   Alshamsan, Aws ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b HAMDARD UNIVERSITY   (India)

^c INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

Author keywords

Box Behnken design; gatifloxacin; response surface plots; solid lipid nanoparticles

Indexed keywords

BOX-BEHNKEN DESIGN; ENCAPSULATION EFFICIENCY; ENTRAPMENT EFFICIENCY; GATIFLOXACIN; INDEPENDENT VARIABLES; POLYDISPERSITY INDICES; RESPONSE SURFACE PLOT; WIDE-ANGLE X-RAY DIFFRACTION;

BIOCHEMISTRY; DESIGN; DIFFERENTIAL SCANNING CALORIMETRY; DIGITAL STORAGE; ENCAPSULATION; MICROEMULSIONS; NANOPARTICLES; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; SURFACE PROPERTIES; TRANSMISSION ELECTRON MICROSCOPY; X RAY DIFFRACTION;

OPTIMIZATION;

GATIFLOXACIN; LIPID; POLOXAMER; SOLID LIPID NANOPARTICLE;

ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG RELEASE; IN VITRO STUDY; NANOENCAPSULATION; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; STATISTICAL ANALYSIS; TRANSMISSION ELECTRON MICROSCOPY; X RAY DIFFRACTION; ZETA POTENTIAL;

CALORIMETRY, DIFFERENTIAL SCANNING; DRUG DELIVERY SYSTEMS; DRUG STABILITY; EYE; FLUOROQUINOLONES; LIPIDS; NANOPARTICLES; PARTICLE SIZE; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; RHEOLOGY; STATIC ELECTRICITY; STATISTICS AS TOPIC; SUSPENSIONS; X-RAY DIFFRACTION;

EID: 84876297984     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.34453     Document Type: Article

References (29)

1. Gan L, Gan Y, Zhu C, Zhang X, Zhu J,. Novel microemulsion in situ electrolyte-triggered gelling system for ophthalmic delivery of lipophilic cyclosporine A: In vitro and in vivo results. Int J Pharm 2009; 365: 143-149.
2. Attama AA, Schicke BC, Paepenmuller T, Muller-Goymann CC,. Solid lipid nanodispersions containing mixed lipid core and a polar heterolipid: Characterization. Eur J Pharm Biopharm 2007; 67: 48-57.
3. Gokce EH, Sandri G, Bonferoni MC, Rossi S, Ferrari F, Guneri T, Caramella C,. Cyclosporine A loaded SLNs: Evaluation of cellular uptake and corneal cytotoxicity. Int J Pharm 2008; 364: 76-86.
4. Muller RH, Runge SA, Ravelli V, Thunemann AF, Mehnert W, Souto EB,. Cyclosporine-loaded solid lipid nanoparticles (SLN): Drug-lipid physicochemical interactions and characterization of drug incorporation. Eur J Pharm Biopharm 2008; 68: 535-544.
5. Yamaguchi M, Yasueda S, Isowaki A, Yamamoto M, Kimura M, Inada K, Ohtori A,. Formulation of an ophthalmic lipid emulsion containing an anti-inflammatory steroidal drug, difluprednate. Int J Pharm 2005; 301: 121-128.
6. Motwani SK, Chopra S, Talegaonkar S, Kohli K, Ahmad FJ, Khar RK,. Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: Formulation, optimisationand in vitro characterization. Eur J Pharm Biopharm 2008; 68: 513-525.
7. Friedrich I, Reichl S, Muller-Goymann CC,. Drug release and permeation studies of nanosuspensions based on solidified reverse micellar solutions (SRMS). Int J Pharm 2005; 305: 167-175.
8. Kalam MA, Sultana Y, Samad A, Ali A, Aqil M, Mishra AK, Chuttani K,. Preparation, characterization, and evaluation of GAT loaded solid lipid nanoparticles as colloidal ocular drug delivery system. J Drug Target 2010; 18: 191-204.
9. Kalam MA, Sultana Y, Samad A, Ali A, Aqil M, Sharma M, Mishra AK,. 2008. Gelrite-based in-vitro gelation ophthalmic drug delivery system of gatifloxacin. J Disp Sci Technol 2008; 29: 89-96.
10. Muller-Goymann CC,. Physicochemical characterization of colloidal drug delivery systems such as reverse micelles, vesicles, liquid crystals and nanoparticles for topical administration. Eur J Pharm Biopharm 2004; 58: 343-356.
11. Candioti LV, Robles JC, Mantovani VE, Goicoechea HC,. Multiple response optimization applied to the development of a capillary electrophoretic method for pharmaceutical analysis. Talanta 2006; 69: 140-147.
12. Chopra S, Patil GV, Motwani SK,. Release modulating hydrophilic matrix systems of losartan potassium: Optimisation of formulation using statistical experimental design. Eur J Pharm Biopharm 2007; 66: 73-82.
13. Chopra S, Motwani SK, Iqbal Z, Talegaonkar S, Ahmad FJ, Khar RK,. Optimisation of polyherbal gels for vaginal drug delivery by Box-Behnken statistical design. Eur J Pharm Biopharm 2007; 67: 120-131.
14. Box GEP, Behnken DW,. Some new three level designs for the study of quantitative variables. Technometrics 1960; 2: 455-475.
15. Cavalli R, Gasco MR, Chetoni PC, Burgalassi S, Saettone MF,. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm 1999; 238: 241-245.
16. Dingler A, Gohla S,. Production of solid lipid nanoparticles (SLN): Scaling up feasibilities. J Microencapsul 2002; 19: 11-16.
17. Gasco MR,. Method for producing solid lipid microspheres having a narrow size distribution. US Pat US-188,837 (1993).
18. Freitas C, Muller RH,. Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. Eur J Pharm Biopharm 1999; 47: 125-132.
19. Shah AK, Date AA, Joshi MD, Patravale VA,. Solid lipid nanoparticles (SLN) of tretinoin: Potential in topical delivery. Int J Pharm 2007; 345: 163-171.
20. Liu J, Gong T, Wang C, Zhong Z,. Solid lipid nanoparticles loaded with insulin by sodium cholate-phosphatidylcholine-based mixed micelles: Preparation and characterization. Int J Pharm 2007; 340: 153-162.
21. Pignatello R, Bucolo C, Ferrara P, Maltese A, Puleo A, Puglisi G,. Eudragit RS100® nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J Pharm Sci 2002; 16: 53-61.
22. Prabha S, Zhou WZ, Panyam J, Labhasetwar V,. Size-dependency of nanoparticle-mediated gene transfer: Studies with fractionated nanoparticles. Int J Pharm 2002; 244: 105-115.
23. Pignatello R, Bucolo C, Spedalieri G, Maltese A, Puglisi,. Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials 2002; 23: 3247-3255.
24. Cavalli R, Caputo O, Carlotti ME, Trotta M, Scarnecchia C, Gasco MR,. Sterilization and freeze-drying of drug-free and drug-loaded solid lipid nanoparticles. Int J Pharm 1997; 148: 47-54.
25. Bunjes H, Westesen K, Koch MHJ,. Crystallization tendency and polymorphic transitions in triglyceride nanoparticles. Int J Pharm 1996; 129: 159-173.
26. Nidham-Hildeshein V, Wizel S, Sterimbaum G,. US Pat US 0,192,700 A1 (2004).
27. Muller RH, Mader K, Gohla S,. 2000. Solid lipid nanoparticles (SLN) for controlled drug delivery-A review of the state of the art. Eur J Pharm Biopharm 2000; 50: 161-177.
28. Peppas NA,. Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv 1985; 60: 110-111.
29. Van-Ooteghem MM,. Formulation of Ophthalmic Solutions and Suspensions. Problems and Advantages. In:, Edman P, editor. Biopharmaceutics of Ocular Drug Delivery. Boca Raton: CRC Press; 1993. p 27-41.